

## Tyvaso

## **Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info:   Same as Reques	sting Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: ☐ Same as Referr Name:	ring Provider Same as Requesting Provider NPI#:
Fax:	Phone:
	ssing limits in accordance with FDA-approved labeling, a, and/or evidence-based practice guidelines.
Patient Weight:	kg
Patient Height:	cm
Please indicate the place of service for the req  ☐ Ambulatory Surgical ☐ Home ☐ Inc.	uested drug: patient Hospital
□On Campus Outpatient Hospital □O	

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tyvaso SGM-10/2020.

	mical Criteria Questions:  What is the diagnosis?  □ Pulmonary arterial hypertension (PAH)  □ Other	
2.	What is the ICD-10 code?	
3.	Is the request for continuation of therapy with Tyvaso? ☐ Yes ☐ No If No, skip to #6	
4.	Is the patient currently receiving the requested product through a paid pharmacy or medical benefit?  ☐ Yes ☐ No ☐ Unknown If No or Unknown, skip to #6	
5.	Is the patient experiencing benefit from the rapy as evidenced by disease stability or disease improvement?  No further questions  Yes, disease stability  Yes, disease improvement  No, neither disease stability nor disease improvement	
6.	What is the World Health Organization (WHO) classification of pulmonary hypertension?  □ WHO Group 1 (Pulmonary arterial hypertension)  □ WHO Group 2 (Pulmonary hypertension owing to left heart disease)  □ WHO Group 3 (Pulmonary hypertension owing to lung disease and/or hypoxia)  □ WHO Group 4 (Chronic thromboembolic pulmonary hypertension)  □ WHO Group 5 (Pulmonary hypertension with unclear multifactorial mechanisms)	
7.	Has PAH been confirmed by right heart catheterization? ☐ Yes ☐ No If No, skip to #11	
8.	What is the pretreatment mean pulmonary arterial pressure at rest? mmHg	
9.	What is the pretreatment capillary wedge pressure?mmHg	
10.	What is the pretreatment pulmonary vascular resistance?Wood units No further questions	
11.	Is the patient an infant less than one year of age? ☐ Yes ☐ No	
12.	Does the patient have ANY of the following conditions? <i>Indicate below or mark "None of the above."</i> ☐ Post cardiac surgery ☐ Chronic heart disease ☐ Chronic lung disease as sociated with prematurity ☐ Congenital diaphragmatic hernia ☐ None of the above	
13.	Has Doppler echocardiogram been performed to diagnose PAH? ☐ Yes ☐ No	
	ttest that this information is accurate and true, and that documentation supporting this ormation is available for review if requested by CVS Caremark or the benefit plan sponsor.	
X_ Pre	escriber or Authorized Signature Date (mm/dd/yy)	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tyvaso SGM-10/2020.

CVS Caremark Specialty Pharmacy

• 2211 Sanders Road NBT-6

• Northbrook, IL 60062

Phone: 1-888-877-0518

• Fax: 1-855-330-1720

• www.caremark.com